ライフサイエンスコーパス: smoking history

1 type, anti-CMV IgG positivity, age, sex, and smoking history.

2 he best outcomes occur when the donor has no smoking history.

3 rease in miRNA abundance was associated with smoking history.

4 nset, despite their young age and paucity of smoking history.

5 tial transplant from a donor with a negative smoking history.

6 emor, a history of constipation, and lack of smoking history.

7 of vimentin and fibronectin, irrespective of smoking history.

8 ith lung cancer risk independent of reported smoking history.

9 = 0.039) compared with participants with no smoking history.

10 obstruction (a COPD hallmark) in relation to smoking history.

11 ity, education, childhood family income, and smoking history.

12 elationships between CT findings and age and smoking history.

13 ure include larger diameter, female sex, and smoking history.

14 e compared after adjusting for age, sex, and smoking history.

15 were reviewed for pathology, BC therapy, and smoking history.

16 send deprivation scores, alcohol intake, and smoking history.

17 and 24 controls matched for age, gender, and smoking history.

18 ation), unmarried status, HIV infection, and smoking history.

19 lts were unaffected by neuroleptic status or smoking history.

20 or potential confounders, including detailed smoking history.

21 seemed to be more pronounced in women with a smoking history.

22 nce persisted after covarying for height and smoking history.

23 king cessation are largely affected by their smoking history.

24 2.4-22.4, p < 0.001) and was independent of smoking history.

25 questionnaires were used to collect detailed smoking history.

26 apulmonary neoplasm and with patient age and smoking history.

27 he extrapulmonary neoplasm and the patient's smoking history.

28 ypertension treatment, adjusting for age and smoking history.

29 wer heart rate and a higher rate of reported smoking history.

30 FEV1/ FVC </= 0.70 and subjects who had any smoking history.

31 group of HIV- volunteers matched for age and smoking history.

32 weight, infarct-related coronary artery and smoking history.

33 and 2.21 for CHD adjusted for age, sex, and smoking history.

34 toms as well as risk factors such as age and smoking history.

35 wo diagnostic breathing tests, and cigarette smoking history.

36 re frequently observed in LUAD patients with smoking history.

37 for age, sex, body mass, diagnosis year, and smoking history.

38 of age and with greater than a 15 pack-year smoking history.

39 g high-risk individuals according to age and smoking history.

40 re in young smokers, with a relatively short smoking history.

41 with breast cancer and those with long-term smoking history.

42 ho are active smokers) correlated with their smoking history.

43 0 (39%) used lungs from donors with positive smoking histories.

44 risk = 3.0 if age >47 years, P = 0.032) and smoking history (2% increase in risk/pack-year of smokin

45 hole blood of 48 individuals with a detailed smoking history (24 never-smokers, 16 smokers, and 8 ex-

46 By smoking history, 29 subjects were identified as smokers,

47 0,131 patients; age range, 45-81 yr; average smoking history, 44.3 pack-years), we evaluated spiromet

48 Among patients with available quantified smoking history, 48% were age 55-74 years and smoked 30-

49 tion and were adjusted for age, alcohol use, smoking history, age at menopause, marital status, and t

50 Pattern of medication use, smoking history, age, body mass index (BMI), and health

51 ible for lung cancer screening (30 pack-year smoking history, ages 55-74 years, for the reference sce

52 odds ratios (ORs) and 95% CIs, adjusting for smoking history, alcohol consumption, and detection of H

53 e, race, body mass index, physical activity, smoking history, alcohol use, history of myocardial infa

54 sex, education, income level, occupation, or smoking history among the groups (P >0.05).

55 al and biological features such as age, sex, smoking history, anatomic location, histological type an

56 nalyzed for interactions between allergy and smoking histories and inherited variants in 5 establishe

57 We obtained smoking histories and measured urine 4-(methylnitrosamin

58 Cumulative tobacco smoking histories and spirometry were obtained at ages 1

59 , young African American DM patients with no smoking history and a BMI </=25 are at reduced risk, and

60 ocial history was notable for a 20-pack-year smoking history and a recent relocation to a neighborhoo

61 into distinct clusters that correlated with smoking history and alterations of reported lung adenoca

62 f age 55 to 80 years who have a 30 pack-year smoking history and are currently smoking or have quit w

63 index for AN using age, sex, family history, smoking history and BMI was found to be of limited discr

64 , family history of colorectal cancer (CRC), smoking history and body mass index (BMI) may be useful

65 Smoking history and childhood-onset persistent asthma we

66 ed into those with and without a significant smoking history and compared with patients with COPD, th

67 aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within

68 aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within

69 ed considerably more active smokers than did smoking history and detected a high prevalence of second

70 g for known risk factors, including detailed smoking history and dietary factors, participants with a

71 current blood pressure, diabetic status, and smoking history and measurements of total cholesterol, h

72 0.05) after adjustment for age, sex, height, smoking history and medication.

73 er smokers, each with a minimum 30-pack-year smoking history and mild or no abnormalities at PFT, und

74 er risk, including sex, variables related to smoking history and nicotine addiction, medical history,

75 mpleted a detailed questionnaire on parental smoking history and on putative risk factors for myopia.

76 68 participants completed a questionnaire on smoking history and other risk factors.

77 never smoked or had a less than 5 pack years smoking history and present the clinical, radiologic, an

78 d the association of LTBI with self-reported smoking history and smoking intensity in multivariable l

79 Cox models assessed the association between smoking history and the primary trial outcome of DFS (ie

80 s examined the association between cigarette smoking history and three common histologic subtypes of

81 les were taken at the surgery to confirm the smoking history and to quantify cigarette use.

82 classified according to their self-reported smoking history and urinary cotinine concentration withi

83 nd=0.005) after adjustment for self-reported smoking history and urinary total cotinine.

84 moker of 30 cigarettes per day (45 pack-year smoking history), and he consumed four standard drinks o

85 Demographic factors, smoking history, and a detailed occupational history, in

86 factors for AAA include older age, male sex, smoking history, and a family history of AAA.

87 alyses (OSAs) with apolipoprotein E alleles, smoking history, and age at onset as stratifying covaria

88 ible to H1N1pdm09 infection, whereas gender, smoking history, and age do not appear to affect AEC sus

89 ones, height, weight, body mass index (BMI), smoking history, and alcohol intake.

90 ation about donor lungs were collected (age, smoking history, and blood gas before lung harvesting).

91 pparent temperature, season, age, race, sex, smoking history, and body mass index as predictors.

92 h-density lipoprotein cholesterol, diabetes, smoking history, and body mass index were also determine

93 tified by disease stage, performance status, smoking history, and centre, block size 10) to receive o

94 Baseline data included demographics, smoking history, and computed tomography emphysema.

95 ischemic attack or cerebrovascular accident, smoking history, and creatinine clearance (hemoglobin le

96 Reported sputum production, smoking history, and current cigarette consumption stron

97 Assignment to exemestane, having a smoking history, and current employment also were signif

98 Baseline probing depths, smoking history, and demographic data also were collecte

99 were adjusted for age, sex, alcohol intake, smoking history, and educational attainment.

100 0 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor ex

101 ndependently of NSCLC stage, age, sex, race, smoking history, and histologic characteristics of the t

102 ccounting for age, serum cholesterol levels, smoking history, and hypertensive status; adjusted predi

103 fit extended across age, performance status, smoking history, and induction response (stable disease

104 xposed to asbestos, after adjusting for age, smoking history, and intervention arm.

105 uded self-reported demographics, medical and smoking history, and lung cancer-specific and all-cause

106 graphics, health habits, including cigarette smoking history, and medical history, including RA diagn

107 of patient survival independent of age, sex, smoking history, and mutational load.

108 iological and severity-of-illness variables, smoking history, and number of concomitant medications),

109 males, adjusting for confounders (area, age, smoking history, and number of elder siblings) and also

110 of subgroups defined according to age, sex, smoking history, and risk of lung cancer and performed s

111 body-mass index, current smoking status and smoking history, and severity of airflow limitation.

112 ariety of factors, including a comprehensive smoking history, and submitted toenail samples, from whi

113 models demonstrated that patient age, former smoking history, and the IL-1 genotype were significantl

114 ed by knowing the age at disease onset, sex, smoking history, and the presence of HLA-B*4100, DRB1*08

115 010 and analysed retrospectively around age, smoking history, and the use of ICS (including combinati

116 rain death or circulatory death), bilirubin, smoking history, and whether the liver was split.

117 [aOR], 1.32; 95% CI, 1.18-1.47) and current smoking history (aOR, 1.28; 95% CI, 1.12-1.45), with sig

118 Workers' smoking histories are not measured in many occupational

119 Smoking history, assessed using pack-years of smoking, w

120 lifestyle questionnaire including a detailed smoking history at baseline.

121 for postbronchodilator ventilatory function, smoking history, atopy, and treatment.

122 lling for histopathologic diagnosis, gender, smoking history, baseline forced vital capacity, and 6-m

123 ypercholesterolemia, diabetes, hypertension, smoking history, baseline ST segment depression and prev

124 Among patients with a smoking history before transplantation, death-censored g

125 6, after adjustment for age, race/ethnicity, smoking history, benign prostatic hyperplasia, and famil

126 function or as age, sex, chronic conditions, smoking history, blood pressure, body mass index, and ho

127 ing for clinical site, patient age, reported smoking history, body mass index (BMI), diabetes, HIV, a

128 d gender, with no significant differences in smoking history, body mass index, menopausal status, or

129 g cancer relative to smokers with comparable smoking history but possessing the lowest tertiles of ur

130 be higher in men than women with comparable smoking histories, but differences were modest; smoking

131 overall, and within demographic, weight, and smoking history categories, and by histological subtype

132 nction by gender, treatment group, and three smoking history categories: sustained quitters, intermit

133 operative Oncology Group performance status, smoking history, centre, and masked pretreatment serum p

134 In multivariable models, smoking history, conditioning with high-dose total body

135 Careful family history, smoking history, consideration of absolute versus catego

136 phocyte engraftment dynamics, lung function, smoking history, corticosteroids, antiviral treatment, v

137 or pool by exclusion of donors with positive smoking histories could compromise survival of patients

138 k [RR], 2.34; 95% CI, 1.55-3.53), or lack of smoking history (current vs never: RR, 0.44; 95% CI, 0.3

139 agnosis (local, regional, or metastatic) and smoking history (current, previous, or nonsmoker).

140 Demographic characteristics, smoking history, depression symptoms, and body mass inde

141 associated with allergy history but not with smoking history despite putative biologic plausibility.

142 tors for CAD included recipient age, gender, smoking history, diabetes mellitus, hypertension and hyp

143 Dietary methionine, alcohol intake, and smoking history did not modify this relation.

144 tial transplant from a donor with a negative smoking history donor, by analysing all waiting-list reg

145 n of randomized treatment assignments and of smoking history during the study with changes in lung fu

146 Randomisation was stratified by smoking history, ECOG performance status, disease histol

147 factor data (age, sex, race, weight, height, smoking history, education, marital status, diet, alcoho

148 pregnancy BMI in the controls), age, parity, smoking history, educational level, and delivery year.

149 pients of lungs from teenaged donors with no smoking history exhibited a higher morbidity and mortali

150 of lungs from heavy smokers (>40 pack-years smoking history) exhibited a significantly higher incide

151 Patients were stratified on the basis of smoking history, extent of disease, and concomitant medi

152 wever, after adjustment for age and previous smoking history, factors common to both diseases, the as

153 included age, stage, past history of cancer, smoking history, family history of cancer, HRT use, trea

154 ed by geographical variation in gender, age, smoking history, farm exposure, family size and BMI.

155 bjects and further adjusted for age, gender, smoking history, farm exposure, number of older siblings

156 cluding adenocarcinoma histology, absence of smoking history, female sex, and Asian ethnicity.

157 Smoking histories for individual birth cohorts that actu

158 l Health Interview Surveys yielded cigarette smoking histories for the US adult population in 1964-20

159 udied, largely because obtaining an accurate smoking history from critically ill patients is difficul

160 ich was due to the difficulty of identifying smoking history from search terms.

161 as the duration and location of procedures, smoking history, gender, and age were recorded.

162 -3)), although we were unable to stratify by smoking history; genetically predicted smoking initiatio

163 data from COPDGene (n = 10,131; ages 45-81; smoking history, >/=10 pack-years), we evaluated spirome

164 ts receiving lungs from donors with positive smoking histories had a lower unadjusted hazard of death

165 .93, p < 0.001), and adjustment for previous smoking history had little effect on this odds ratio (ad

166 tice.A 78-year-old woman with a 40-pack-year smoking history has been referred for treatment of advan

167 His 75-pack-year smoking history has resulted in a chronic daily cough an

168 Heart recipients with a smoking history have increased risk of developing corona

169 dependently of ABI, age, male sex, diabetes, smoking history, high body mass index, myocardial infarc

170 roportional hazards models adjusted for age, smoking history, history of diabetes mellitus, and/or se

171 analysis were family history of lung cancer; smoking history; history of asbestos exposure; and intak

172 ; sex; treatment arm (captopril or placebo); smoking history; history of prior myocardial infarction,

173 (HR = 2.04), bariatric surgery (HR = 1.78), smoking history (HR = 1.74), liver disease (HR = 1.60),

174 cy that uses lungs from donors with positive smoking histories improves overall survival of patients

175 k than controls matched for age, gender, and smoking history in developing or having an increased pro

176 The risk that a positive smoking history in lung donors could adversely affect su

177 uthors adjusted for pack-years from reported smoking history in multivariate analyses, the relative r

178 y, this study revisited the effects of donor smoking history in relation to age on transplant outcome

179 ge, single-center experience, the absence of smoking history in the donor did not result in better lo

180 Clinicians should consider including smoking history in their discussions with patients about

181 Self-reported smoking history included smoking status, duration, inten

182 on HPV status, tumor stage, nodal stage, and smoking history into risk groups with differing risks of

183 for age, body mass index, hypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.0

184 If smoking history is modeled for 20 or 40 pack-years, incr

185 hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced no

186 On the basis of age and smoking history, it is often easy to distinguish between

187 uch as age, gender, diabetes mellitus, race, smoking history, left ventricular function, estrogen tre

188 ed to analyze coaxial needle size, age, sex, smoking history, lesion size, use of an automated core b

189 asures were related to classic risk factors (smoking history, lipid profile, blood pressure, fasting

190 50 years of age, with more than 20 pack-year smoking histories, living in an urban setting, and with

191 physiologic variables were analyzed, greater smoking history, lower DL(CO), and younger age predicted

192 naive patients with adenocarcinoma and light smoking histories (< or = 20 pack-years).

193 or older, increased weight, rapid pulse, and smoking history (< or =8 points each).

194 001), as were performance status, older age, smoking history, male sex, treatment factors, and stage

195 gingival index scores than age, gender, and smoking history matched controls.

196 After adjustment for age, body mass index, smoking history, medical morbidity, direct measures of p

197 ender, alcohol consumption, medical therapy, smoking history, metabolic risk factors, mobilizable iro

198 th cohort decades (1940s to 1980s) and three smoking history (nonsmokers, never-dependent smokers and

199 h adenoma among certain subgroups defined by smoking history [odds ratio (OR), 4.27; 95% confidence i

200 The smoking histories of 371 RA patients attending a hospita

201 essed using responses about past and current smoking histories of household members and any history o

202 cancer mortality in high-risk participants (smoking history of >/=30 pack-years) aged 55 to 74 years

203 had a nonsmoking spouse, and the other had a smoking history of >10 pack-years.

204 nefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more be

205 Patients with a smoking history of </=11 pack years (the median value) t

206 40 years or older, had a history of COPD, a smoking history of 10 or more pack-years, a ratio of for

207 vital capacity of less than 70%), and had a smoking history of 10 or more pack-years, were receiving

208 ncidence of emphysema in participants with a smoking history of 12 pack-years or greater was 37% (14

209 s 41.6+/-17.7% of the predicted value, and a smoking history of 50.6+/-27.4 pack-years.

210 This patient had a smoking history of 80 pack-years, but she had quit smoki

211 All patients were chronic smokers with a smoking history of about 51 pack-years.

212 rced vital capacity (FVC) of 0.70 or less, a smoking history of at least 10 pack-years, and a score o

213 linical COPD, defined as participants with a smoking history of at least 10 pack-years, FEV1 less tha

214 atients were 40 years of age or older with a smoking history of at least 20 pack-years and a diagnosi

215 atients with COPD aged 40-80 years who had a smoking history of at least 20 pack-years, recruited fro

216 55 through 80 years for ever-smokers with a smoking history of at least 30 pack-years and ex-smokers

217 ymptomatic persons aged 55 to 74 years, with smoking history of at least 30 pack-years.

218 ality in current smokers were evident from a smoking history of less than 10 pack-years, whereas the

219 emale patients because of a disparity in the smoking history of the genotypic groups.

220 raphic variation (north vs south), cigarette smoking, history of diabetes, and education, compared wi

221 they identified three-way interactions among smoking, history of estrogen use, and dietary and serum

222 k included older age, female sex, history of smoking, history of hypertension, overall burden of medi

223 cceptance of lungs from donors with positive smoking histories on survival and compared it with the e

224 mation is available on the impact of current smoking history on these metabolites.

225 ke may be underestimated in studies based on smoking history only.

226 -1.64); male gender (OR 1.26, CI 1.06-1.50); smoking history (OR 1.20, CI 1.02-1.40); and procedure t

227 severe pulmonary regurgitation (OR, 9.0) and smoking history (OR, 27.2).

228 This elevation was independent of age, sex, smoking history, or duration of the disease.

229 l survival did not differ based on age, sex, smoking history, or ethnic origin.

230 Analyses stratified by body mass index, smoking history, or parental history of diabetes showed

231 d menopause, menopausal status at diagnosis, smoking history, or prior use of the oral contraceptive

232 rtension, diabetes, hypercholesterolemia and smoking history (p < 0.0001).

233 creasing patient age (P < .001) and positive smoking history (P = .001) were associated with increase

234 p < 0.001), diabetes mellitus (p = 0.015) or smoking history (p = 0.033).

235 ogate of human papillomavirus) and cigarette smoking history (pack-years) randomly assigned to clinic

236 Gender and smoking history (pack-years) were included as covariates

237 We obtained data on smoking history, perioperative risk factors, and 30-day

238 mily history of myocardial infarction, race, smoking history, physical activity, and quality of life.

239 Adjusted for age, sex, disease duration and smoking history, pRBD was associated with greater sleepi

240 Sex, histology, skin rash, and smoking history predicted outcome with erlotinib.

241 s to define potential confounders, including smoking history, presence and severity of lung and heart

242 elations persisted after correction for age, smoking history, presence of lung cancer, recent respira

243 year-old man with a 45 pack per year tobacco-smoking history presented with painless gross hematuria

244 A 54-year-old man with a former 15-pack-year smoking history presents with cough and dyspnea.

245 matic subgroup, predictors of mortality were smoking history, previous carotid endarterectomy, hemogl

246 also confirmed that both IL-1 genotyping and smoking history provide objective risk factors for perio

247 fe, dyspnea, oxygen utilization, hemoglobin, smoking history, quantitative emphysema markers on compu

248 or 6 confounders: age, sex, education level, smoking history, RA severity, and prednisone use.

249 ried out with respect to age, disease stage, smoking history, radiation therapy technique, dose, the

250 These findings were apparent despite similar smoking histories, self-reported oral hygiene practices,

251 defined by variables such as age, diabetes, smoking history, serum creatine phosphokinase, or electr

252 with education, family income, alcohol use, smoking history, serum levels of cotinine, or C-reactive

253 Patient variables included smoking history, sex, age, primary site, tumor stage, an

254 reased survival, patients with a significant smoking history should be carefully scrutinized for live

255 The recipients of lungs from donors with a smoking history showed better 5-year survival than recip

256 lity remained after adjustment for cigarette smoking history, social class, body mass index, systolic

257 ncluding age, sex, race, performance status, smoking history, stage, treatment history, and overall s

258 tically significant interaction between past smoking history status and IL-1 genotype status.

259 s, including laboratory values, medications, smoking history/status, and postoperative outcomes, were

260 rong predictor of lung cancer independent of smoking history, suggesting that the adverse effects of

261 ally, SS is correlated with current and past smoking histories, systolic blood pressure, HDL levels (

262 onal studies attempt to control for reported smoking histories, the accuracy of self-reported smoking

263 When adjusted for age, sex, diet, and smoking history, the relative risk for AMD decreased 10%

264 splant of lungs from teenaged donors with no smoking history, this study revisited the effects of don

265 harvesting, and comorbid health conditions (smoking history, type 2 diabetes mellitus, hypertension,

266 carcinogen dose than by using self-reported smoking history, ultimately improving the estimation of

267 who received lungs from donors with negative smoking histories (unadjusted hazard ratio [HR] 1.46, 95

268 nts with intracranial aneurysm (53.8%) had a smoking history vs 163 of 564 patients without intracran

269 In addition, past smoking history was also a significant effect modifier a

270 Smoking history was ascertained by self-report.

271 Smoking history was assessed at baseline and updated on

272 Smoking history was assessed at baseline and updated on

273 Smoking history was associated with attachment loss.

274 Smoking history was defined in terms of current smoking

275 Smoking history was more common (P = .0008) in patients

276 ue eosinophilia, whilst no clear relation to smoking history was observed.

277 Information about smoking history was obtained by questionnaire.

278 Smoking history was obtained from chart review or via te

279 Smoking history was obtained from patients, their surrog

280 Smoking history was obtained on each patient.

281 A detailed smoking history was obtained.

282 Subgroup analysis by sex and smoking history was performed.

283 Smoking history was self-reported at baseline; newly dia

284 Detailed lifetime smoking histories were collected by personal interview i

285 exposures to other environmental agents, and smoking histories were evaluated using a self-administer

286 l measurements, demographic information, and smoking histories were recorded.

287 and information on participant schooling and smoking history were collected at 23-25 y of age.

288 tus, weight loss, sex, age at diagnosis, and smoking history were controlled for, patients with LOH w

289 Age and smoking history were independently associated with aorti

290 her body mass index (>/= 25), diabetes, or a smoking history were less likely, to undergo biopsy, adj

291 als matched with respect to age, gender, and smoking history were selected and evaluated for the same

292 fraction (LVEF) <35%, and <10 pack-years of smoking history were studied.

293 lems with lungs from teenaged donors with no smoking history were suggested.

294 and 10 controls matched for age, gender, and smoking history, were chosen to participate in a study e

295 ients with < T4, < N2c, and </= 10 pack-year smoking history who were treated with </= 54 Gy of radia

296 ses on age (+/-5 years), sex, ethnicity, and smoking history, who were recruited from a local multisp

297 tudied 23 current or ex-smokers with similar smoking histories with COPD (n = 11; FEV(1) < 70% predic

298 here were no interactions for glioma risk of smoking history with any of the risk alleles.

299 All findings were independent of pack-year smoking history with multiple logistic regression analys

300 After results were controlled for age and smoking history, women with at least 1 child had 0.71 ti